TNF and infection: Real-life populational cohort data suggest a lower risk of serious infections with tofacitinib (1.75 per 100 patient-years (95% CI, 1.27–2.36)) than with anti-TNF-α (3.33 (95% CI, 2.73–4.02)) [64].